CD30+ Peripheral T-cell Lymphoma
3 clinical trials · Condition
◉ Watch CD30+ Peripheral T-cell Lymphoma
| Record | Firm | Date |
|---|---|---|
| Study of Brentuximab Vedotin Plus TAK228 for Relapsed/Refractory Classical Hodgkin Lymphoma, Anaplastic Large Cell Lymphoma and Other CD30+Peripheral T-Cell Lymphomas (NCT03205891) | M.D. Anderson Cancer Center | 2018-03-01 |
Track CD30+ Peripheral T-cell Lymphoma automatically
Every clearance here is in the API, with alerts when new ones post.